AU2020228296B2 - Administration of PD-1 inhibitors for treating skin cancer - Google Patents

Administration of PD-1 inhibitors for treating skin cancer

Info

Publication number
AU2020228296B2
AU2020228296B2 AU2020228296A AU2020228296A AU2020228296B2 AU 2020228296 B2 AU2020228296 B2 AU 2020228296B2 AU 2020228296 A AU2020228296 A AU 2020228296A AU 2020228296 A AU2020228296 A AU 2020228296A AU 2020228296 B2 AU2020228296 B2 AU 2020228296B2
Authority
AU
Australia
Prior art keywords
antibody
cscc
seq
antigen
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020228296A
Other languages
English (en)
Other versions
AU2020228296A1 (en
Inventor
Matthew G. Fury
Israel Lowy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of AU2020228296A1 publication Critical patent/AU2020228296A1/en
Application granted granted Critical
Publication of AU2020228296B2 publication Critical patent/AU2020228296B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2020228296A 2019-02-28 2020-02-27 Administration of PD-1 inhibitors for treating skin cancer Active AU2020228296B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962811827P 2019-02-28 2019-02-28
US62/811,827 2019-02-28
PCT/US2020/020018 WO2020176699A1 (en) 2019-02-28 2020-02-27 Administration of pd-1 inhibitors for treating skin cancer

Publications (2)

Publication Number Publication Date
AU2020228296A1 AU2020228296A1 (en) 2021-10-14
AU2020228296B2 true AU2020228296B2 (en) 2025-10-02

Family

ID=70057261

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020228296A Active AU2020228296B2 (en) 2019-02-28 2020-02-27 Administration of PD-1 inhibitors for treating skin cancer

Country Status (12)

Country Link
US (1) US20220259313A1 (https=)
EP (1) EP3930848A1 (https=)
JP (2) JP2022521800A (https=)
KR (1) KR20210134690A (https=)
CN (1) CN113490529A (https=)
AU (1) AU2020228296B2 (https=)
CA (1) CA3137361A1 (https=)
IL (1) IL285050A (https=)
MA (1) MA55084A (https=)
MX (1) MX2021010228A (https=)
SG (1) SG11202108089SA (https=)
WO (1) WO2020176699A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
LT3394103T (lt) 2015-12-22 2023-09-11 Regeneron Pharmaceuticals, Inc. Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
WO2020118208A1 (en) 2018-12-07 2020-06-11 Arizona Board Of Regents On Behalf Of The University Of Arizona A method of determining risk for skin cancer development and skin cancer therapeutic prevention by measuring pd-1/pd-l1 signaling pathway members
WO2022173931A1 (en) * 2021-02-11 2022-08-18 Regeneron Pharmaceuticals, Inc. Methods of treating cancer by administering a neoadjuvant pd-1 inhibitor
WO2024186917A2 (en) * 2023-03-06 2024-09-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions for pd-l1 inhibition and methods of use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017197263A1 (en) * 2016-05-13 2017-11-16 Regeneron Pharmaceuticals, Inc. Methods of treating skin cancer by administering a pd-1 inhibitor
US9987500B2 (en) * 2014-01-23 2018-06-05 Regeneron Pharmaceuticals, Inc. Human antibodies to PD-1
WO2018156494A1 (en) * 2017-02-21 2018-08-30 Regeneron Pharmaceuticals, Inc. Anti-pd-1 antibodies for treatment of lung cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL354286A1 (en) 1999-08-23 2003-12-29 Dana-Farber Cancer Institutedana-Farber Cancer Institute Pd-1, a receptor for b7-4, and uses therefor
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
US8552154B2 (en) 2008-09-26 2013-10-08 Emory University Anti-PD-L1 antibodies and uses therefor
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
CA2840018C (en) 2011-07-24 2019-07-16 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
KR20220084444A (ko) 2012-05-31 2022-06-21 소렌토 쎄라퓨틱스, 인코포레이티드 Pd-l1에 결합하는 항원 결합 단백질
RU2689760C2 (ru) 2012-05-31 2019-05-30 Дженентек, Инк. Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
KR102476226B1 (ko) 2014-08-05 2022-12-12 아폴로믹스 인코포레이티드 항-pd-l1 항체
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
ES2986067T3 (es) * 2015-12-17 2024-11-08 Novartis Ag Moléculas de anticuerpos frente a PD-1 y usos de las mismas
LT3394103T (lt) * 2015-12-22 2023-09-11 Regeneron Pharmaceuticals, Inc. Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
SG11201808626WA (en) 2016-04-07 2018-10-30 Chemocentryx Inc Reducing tumor burden by administering ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
CN111201035A (zh) * 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Il-2超激动剂、激动剂及其融合体的用途和方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9987500B2 (en) * 2014-01-23 2018-06-05 Regeneron Pharmaceuticals, Inc. Human antibodies to PD-1
WO2017197263A1 (en) * 2016-05-13 2017-11-16 Regeneron Pharmaceuticals, Inc. Methods of treating skin cancer by administering a pd-1 inhibitor
WO2018156494A1 (en) * 2017-02-21 2018-08-30 Regeneron Pharmaceuticals, Inc. Anti-pd-1 antibodies for treatment of lung cancer

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma ", CLINICALTRIALS.GOV, 5 October 2018 (2018-10-05), pages 1 - 13, XP055919719 *
CASSLER NICOLE M ET AL: "Merkel Cell Carcinoma Therapeutic Update", CURRENT TREATMENT OPTIONS IN ONCOLOGY MAY 2005, SPRINGER US, BOSTON, vol. 17, no. 7, 4 June 2016 (2016-06-04), pages 1 - 18 *
EGGERMONT ALEXANDER M.M., BLANK CHRISTIAN U., MANDALA MARIO, LONG GEORGINA V., ATKINSON VICTORIA, DALLE STÉPHANE, HAYDON ANDREW, L: "Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma", *
MERCK SHARP & DOHME LLC: "History of Changes for Study: NCT03833167 Pembrolizumab Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)" *
SANDRO V PORCEDDU, MICHAEL J VENESS , ALEXANDER GUMINSKI : "Nonmelanoma Cutaneous Head and Neck Cancer and Merkel Cell Carcinoma: Current Concepts, Advances, and Controversies", J CLIN ONCOL ., vol. 33, no. 29, 10 October 2015 (2015-10-10) *

Also Published As

Publication number Publication date
SG11202108089SA (en) 2021-08-30
JP2022521800A (ja) 2022-04-12
KR20210134690A (ko) 2021-11-10
JP2025041768A (ja) 2025-03-26
US20220259313A1 (en) 2022-08-18
CA3137361A1 (en) 2020-09-03
WO2020176699A1 (en) 2020-09-03
CN113490529A (zh) 2021-10-08
IL285050A (en) 2021-09-30
AU2020228296A1 (en) 2021-10-14
EP3930848A1 (en) 2022-01-05
MA55084A (fr) 2022-01-05
MX2021010228A (es) 2021-10-26

Similar Documents

Publication Publication Date Title
AU2020228296B2 (en) Administration of PD-1 inhibitors for treating skin cancer
JP2022532490A (ja) 癌の治療における有効性の増強のためのｐｄ－１阻害剤とｌａｇ－３阻害剤の組み合わせ
JP2025041768A5 (https=)
US20260042841A1 (en) Intralesional administration of pd-1 inhibitors for treating skin cancer
US20250326846A1 (en) Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
IL323023A (en) Combination of PD-1 and LAG-3 inhibitors for improved efficacy in melanoma treatment
CN117042795A (zh) 通过施用pd-1抑制剂治疗免疫抑制或免疫受损患者的癌症的方法
CN119677533A (zh) 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合
TWI916314B (zh) 使用抗ｐｄ－１抗體與抗組織因子抗體－藥物共軛體之組合以治療癌症之方法
HK40112560A (en) Intralesional administration of pd-1 inhibitors for treating skin cancer
HK40057287B (en) Intralesional administration of pd-1 inhibitors for treating skin cancer
HK40057287A (en) Intralesional administration of pd-1 inhibitors for treating skin cancer
HK40109251A (zh) 用抗pd-1抗体和抗cd30抗体-药物缀合物的组合治疗癌症的方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)